The Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis Factor Inhibiting Therapy in Korea
|
|
- Camron Jones
- 6 years ago
- Views:
Transcription
1 Journal of Rheumatic Diseases Vol. 22, No. 5, October, Original Article The Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis Factor Inhibiting Therapy in Korea Bon San Koo 1 *, Seokchan Hong 2 *, You Jae Kim 2, Chang-Keun Lee 2, Bin Yoo 2, Yong-Gil Kim 2 1 Division of Rheumatology, Department of Internal Medicine, Konkuk University Chungju Hospital, Konkuk University College of Medicine, Chungju, 2 Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Objective. The purpose of this study is to evaluate the outcome of uveitis in ankylosing spondylitis (AS) during tumor necrosis factor (TNF)-inhibiting therapy and to compare the incidence rate of uveitis in infliximab, adalimumab, and etanercept. Methods. A retrospective evaluation was performed in AS patients who had started TNF-inhibiting therapy from June 2003 to June The clinical characteristics of patients with documented uveitis were evaluated. Results. Among 316 patients treated with TNF inhibitor, 26 patients (8%) had experienced uveitis during TNF-inhibiting therapy. Among them, 15 patients were treated with etanercept, eight with adalimumab, and three with infliximab. The overall incidence rate of uveitis flare during therapy with TNF inhibitor was 46 per 1,000 person-years (pys) (95% confidence interval [CI], 32 to 64). The incidence rate did not differ between TNF inhibitors, with 54/1,000 pys (95% CI, 34 to 81) for etanercept, 46/1,000 pys (95% CI, 21 to 87) for adalimumab, and 22/1,000 pys (95% CI, 5 to 64) for infliximab. Fourteen patients experienced a first episode of uveitis. The overall incidence rate of new onset-uveitis after therapy with TNF inhibitor was 19 per 1,000 pys (95% CI, 10 to 31). The incidence rate for etanercept was 24/1,000 pys (95% CI, 12 to 45); adalimumab, 15/1,000 pys (95% CI, 3 to 45); and infliximab, 7/1,000 pys (95% CI, 0 to 40). There was no statistical difference in the incidence of uveitis flare or the cumulative uveitis-free rate among the three TNF inhibitors. Conclusion. The relative rate of uveitis, including the first episode, was determined using the TNF inhibitor. However, there was no difference in the incidence rate of uveitis among the three TNF inhibitors. (J Rheum Dis 2015;22: ) Key Words. Tumor necrosis factor, Ankylosing spondylitis, Uveitis INTRODUCTION Uveitis is the most common extra-articular manifestation occurring in patients with ankylosing spondylitis (AS) [1,2]. Patients with AS have a 20% to 30% chance of developing uveitis during the course of their disease, and 85% of the AS patients who experience uveitis are diagnosed with acute anterior uveitis [1]. It generally affects men and is unilateral, painful, and self-limiting. Tumor necrosis factor (TNF) inhibitors have been known to be effective agents in treating articular as well as extra-articular manifestations of AS. However, differing from monoclonal antibodies, concerns have been raised that etanercept may have a less protective effect on uveitis flare [3-7]. Although the pathogenic mechanisms have not yet been fully identified, a recombinant soluble receptor to TNF might be related to lack of its effect on uveitis flare or its paradoxically adverse effect of ocular inflammation. In our study, we investigated the incidence rate of uveitis in AS patients treated with TNF inhibitors in Korea. We also compared the incidence rate of uveitis in patients treated with infliximab, adalimumab, and etanercept. Received:March 12, 2015, Revised:June 4, 2015, Accepted:June 5, 2015 Corresponding to:yong-gil Kim, Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. bestmd2000@amc.seoul.kr *The first two authors contributed equally to this work. pissn: X, eissn: Copyright c 2015 by The Korean College of Rheumatology. All rights reserved. This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited. 288
2 Uveitis during TNF Inhibitor MATERIALS AND METHODS We retrospectively reviewed the electronic medical reports (EMR) of 316 AS patients treated with TNF-inhibiting therapy in a tertiary care center in Korea from June 2003 to June All of the patients had been previously diagnosed as having AS which satisfied the modified New York criteria [8] and had received at least one TNF inhibitor, including etanercept, adalimumab or infliximab, due to the lack of efficacy or the adverse effect of non-steroidal, anti-inflammatory drugs and disease modifying, anti-rheumatic drugs. This study was approved by the Asan Medical Center Institutional Review Board (IRB ). A previous history of uveitis was evaluated at the first medical examination and it was recorded in the EMR. We defined uveitis patients as those with at least one episode of uveitis diagnosed by an ophthalmologist. Clinical data, including patient age, sex, disease duration, human leukocyte antigen (HLA)-B27 allele, body-mass index, and duration of TNF inhibitor exposure, were collected. When comparing the three TNF inhibitors, the chi-square test or Kruskal-the Wallis test was performed. The incidence rates of uveitis were calculated as the number of events or patients per 1,000 person-years (pys) of follow-up with a 95% confidential interval (CI) in the infliximab, adalimumab, and etanercept groups. To estimate the difference in the uveitis risk in the three groups, a survival analysis was performed using the Kaplan-Meier method and Cox proportional hazards model. The log-rank test was used to compare survival curves. A p<0.05 was considered statistically significant. All statistical analyses were performed using Predictive Analytics Software SPSS Statistics ver (SPSS Inc., Chicago, IL, USA). RESULTS Among the 316 AS patients treated with TNF inhibitor, 42 patients (13%) experienced uveitis before TNF-inhibiting therapy. Table 1 shows a comparison of the infliximab, adalimumab, and etanercept groups. Infliximab was used for 85 patients, adalimumab for 148 patients, and etanercept for 142 patients. Male predominance and high HLA-B27 positivity were similar in all of the groups. As each TNF inhibitor was approved by Korean National Health Insurance at points in time, the exposure duration differed in each group. In patients treated with infliximab and adalimumab, the number of patients who experienced uveitis was decreased following their treatment, although not in those treated with etancercept. The overall incidence rate of uveitis flare in all TNF inhibitors was 46 per 1,000 pys (95% CI, 32 to 64). The incidence rate for etanercept was Table 1. Comparison of the clinical characteristics of AS patients treated with infliximab, adalimumab, or etanercept Characteristic Total (n=316) Infliximab (n=85) Adalimumab (n=148) Etanercept (n=142) p-value Age at the start of TNFi (yr) 36.1± ± ± ± Male (%) HLA-B27 positivity (%) AS disease duration (mo) 75.7± ± ± ± Duration of TNFi exposure (mo) 23.9± ± ± ± Body mass index (kg/m 2 ) 24.2± ± ± ± Previous history of uveitis 42 (13) 6 (7) 21 (14) 15 (11) Uveitis during TNFi therapy 26 (8) 3 (4) 8 (5) 15 (11) Uveitis during TNFi therapy (episode) 34 (11) 3 (4) 9 (6) 22 (15) Incidence rate of uveitis during TNFi 46 (32 64) 22 (5 64) 46 (21 87) 54 (34 81) 0.257* therapy (per 1,000 pys) New onset of uveitis during TNFi 14 (4) 1 (1) 3 (2) 10 (7) therapy Incidence rate of new onset of uveitis during TNFi therapy (per 1,000 pys) 19 (10 31) 7 (0 40) 15 (3 45) 24 (12 45) 0.357* Values are presented as mean±standard deviation, percent only, number (%), or median (95% CI). AS: ankylosing spondylitis, HLA: human leukocyte antigen, TNFi: tumor necrosis factor inhibitor, CI: confidence interval, pys: person-years. *Using Poisson regression; including 59 patients who were treated with second or third TNFi
3 Bon San Koo et al. 54/1,000 pys (95% CI, 34 to 81) for adalimumab, 46/1,000 pys (95% CI, 21 to 87), and for infliximab, 22/1,000 pys (95% CI, 5 to 64). The incidence rate of uveitis flare did not different among the three groups even in cases of new onset. Of the 42 patients who experienced uveitis, nine patients were changed to another TNF inhibitor, i.e. five due to uveitis, three due to the lack of efficacy of axial symptoms, and one due to an injection site reaction. Interestingly, among the five patients who switched the TNF inhibitor due to uveitis, four patients changed etancercept to adalimumab and one changed etanercept to infliximab. And after alternative TNF-inhibiting therapy, they never suffered from uveitis again. Among the three patients who changed their TNF inhibitor due to its lack of efficacy, one suffered from uveitis flare after changing adalimumab to etancercept. Fourteen patients experienced their first episode of uveitis after TNF-inhibiting therapy and which was observed more often in the etanercept group (10 patients) and also in the adalimumab group (three patients) and the infliximab group (one patient). The overall incidence rate of new onset uveitis after TNF-inhibiting therapy was 19 per 1,000 pys (95% CI, 10 to 31). The incidence rate for etanercept was 24/1,000 pys (95% CI, 12 to 45), that for adalimumab was 15/1,000 pys (95% CI, 3 to 45), and that for infliximab was 7/1,000 pys (95% CI, 0 to 40), respectively. The incidence rate of patients who used etanercept was 1.6 to 3.4 times higher than that of infliximab and adalimumab; however, there was statistically no difference of incidence rate in three TNF inhibitors. The duration of TNF-inhibiting therapy before the new onset of uveitis was not statistically different. The cumulative, uveitis-free rate was analyzed in the three TNF inhibitors and there was no difference in the development of uveitis (Figure 1A). Moreover, the rate of developing uveitis in patients who had not previously experienced it before starting the TNF inhibitor also did not differ between them (Figure 1B). The risk of developing uveitis and new onset of uveitis during TNF inhibiting therapy increased with treatment with adalimumab and etanercept without significant difference (Table 2). The hazard ratio adjusted for disease duration and duration of TNF inhibitor exposure was also analyzed (hazard ratio 0.9 to 3.1) and there was no significant difference. DISCUSSION In our AS cohort, 26 patients (8%) developed uveitis and 14 patients (4%) experienced new onset of uveitis during TNF-inhibiting therapy. Although there have been previous reports regarding uveitis flare during etanercept therapy, in our study there was no difference in the rate of developing uveitis in the three TNF inhibitors. The TNF inhibitor is a highly effective agent for controlling the activity of AS, including extra-articular manifestations (EAM). The TNF inhibitor can also decrease the incidence of uveitis flare which is a major EAM of AS [9-11]. Although our study did not compare numerous episodes of uveitis flare before and after each TNF inhibitor exposure, the number of patients who developed uveitis during TNF-inhibitor therapy was low (8%) com- Figure 1. Cumulative uveitis-free survival rate after tumor necrosis fator (TNF) inhibitors (A) in all patients and (B) in patients who had never experienced uveitis before TNF-inhibiting therapy. 290 J Rheum Dis Vol. 22, No. 5, October, 2015
4 Uveitis during TNF Inhibitor Table 2. Cox proportional hazard analysis for uveitis of ankylosing spondylitis patients treated with infliximab, adalimumab, or etanercept Characteristic Infliximab (n=85) Adalimumab (n=148) Etanercept (n=142) 95% CI p 95% CI p HR developing uveitis during TNFi therapy Reference 2.0 ( ) ( ) Adjusted HR developing uveitis during TNFi Reference 1.8 ( ) ( ) therapy* HR of new onset of uveitis Reference 2.8 ( ) ( ) Adjusted HR of new onset of uveitis* Reference 0.9 ( ) ( ) CI: confidence interval, HR: hazard ratio, TNFi: tumor necrosis factor inhibitor. *Adjusted for ankylosing spondylitis disease duration and duration of TNFi exposure. pared to AS patients in general, who usually have a 20% to 30% chance of developing uveitis [1]. However, some studies have reported that etanercept did not reduce the incidence of uveitis differently from that of TNF monoclonal antibodies. Guignard et al. [11] reported a difference in the efficacies of the three TNF inhibitors in 46 spondyloarthropathy patients who had at least one uveitis flare. They suggested that etanercept did not reduce the number of flares, whereas infliximab and adalimumab greatly reduced the number of flares. However, it has also been seen in AS clinical trials that etanercept is effective for lowering the uveitis flare rate in AS patients [12]. Our study showed that developing a uveitis flare and the new onset of uveitis did not statistically differ in the three TNF inhibitors. However, five of our patients who were previously treated with etanercept were switched to infliximab or adalimumab alternatively after their uveitis flare, and after which they experienced no subsequent flare. Considering the results of previous reports related to TNF inhibitor and uveitis, these clinical experiences support the supposition that etanercept might be less effective for treating uveitis compared to the other TNF inhibitors. Etanercept is a soluble TNF receptor molecule, whereas infliximab and adalimumab are monoclonal antibodies. Because their mechanisms of antagonizing TNF-α differ, there are pharmacodynamic and pharmacokinetic differences between the TNF inhibitors that may potentially contribute to their action in different disease states [4,13,14]. This evidence suggests that the monoclonal antibodies may be more appropriate than etanercept for treating EAM, including uveitis [15]. Although our study showed that there was no difference in the uveitis flare among the three TNF inhibitors, changing from etanercept to a monoclonal antibody, including infliximab and adalimumab, could be effective for preventing uveitis flare in patients experienced uveitis before. Even if the cohort was small, our patients characteristics showed a male predominance and a high percentage of HLA-B27 positivity similar to that seen in other reports of AS patients who developed uveitis during TNF-inhibiting therapy [4,5,12,16]. In addition, most studies reporting uveitis onset stated that the duration of TNF-inhibitor exposure was from one to 96 months [16]. In our study, with regard to the new onset of uveitis, the mean duration of TNF-inhibiting therapy was 30.5 months and the range was four to 71 months. Our study has several limitations. First, because of retrospective study in single center, small number of patients and loss of follow-up might be influence the incidence rate of uveitis. Second, we could not determine the cause for developing uveitis during TNF-inhibiting therapy and whether it was an adverse effect or the lack of efficacy of the TNF inhibitor. Third, the physician s preference for patients, based on their age and comorbidity, could have affected the choice of TNF inhibitor. CONCLUSION In conclusion, a considerable proportion of the AS patients experienced uveitis flare and approximately half of them developed new uveitis onset even during their treatment with the TNF inhibitor. Although there was no difference in the uveitis flare in the three TNF inhibitors in our study, it might be helpful for patients developing uveitis during etanercept therapy to change to monoclonal antibodies
5 Bon San Koo et al. CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported. REFERENCES 1. Rosenbaum JT. Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 1992;18: Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67: Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo- Ortega H. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008;67: Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35: Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56: Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47: Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39: van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27: Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004;50: Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52: Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65: Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010;69: Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 2005;6: Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124: Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48: Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume- Czitrom S, Prati C, et al; CRI. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41: J Rheum Dis Vol. 22, No. 5, October, 2015
Case Report Inefficacy or Paradoxical Effect? Uveitis in Ankylosing Spondylitis Treated with Etanercept
Case Reports in Medicine, Article ID 471319, 4 pages http://dx.doi.org/10.1155/2014/471319 Case Report Inefficacy or Paradoxical Effect? Uveitis in Ankylosing Spondylitis Treated with Etanercept Bernd
More informationGrigorios T. Sakellariou, 1 Athanasios D. Anastasilakis, 2 Ilias Bisbinas, 3 Anastasios Gketsos, 4 and Charalampos Berberidis 1. 1.
ISRN Rheumatology Volume 2013, Article ID 907085, 4 pages http://dx.doi.org/10.1155/2013/907085 Clinical Study Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying
More informationManifestations of Cervical Spine Involvement in Longstanding Ankylosing Spondylitis: Atlantoaxial Ankylosis and Atlantoaxial Subluxation
Journal of Rheumatic Diseases Vol. 24, No. 1, February, 2017 https://doi.org/10.4078/jrd.2017.24.1.21 Original Article Manifestations of Cervical Spine Involvement in Longstanding Ankylosing Spondylitis:
More informationHeel pain in spondyloarthritis: results of a cross-sectional study of 275 patients
Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients E. Koumakis, L. Gossec, M. Elhai, V. Burki, A. Durnez, I. Fabreguet, M. Meyer, J. Payet, F. Roure, S. Paternotte, M. Dougados
More informationGender Differences in Clinical Features and Anti-TNF Agent Use in Korean Ankylosing Spondylitis Patients
Journal of Rheumatic Diseases Vol. 19, No. 3, June, 2012 http://dx.doi.org/10.4078/jrd.2012.19.3.132 Original Article Gender Differences in Clinical Features and Anti-TNF Agent Use in Korean Ankylosing
More informationAcute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients
Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients C. Frantz 1, A. Portier 2, A. Etcheto 3, D. Monnet 4, A. Brezin 4, F. Roure 1, M. Elhai 1, V. Burki 1, I. Fabreguet 1, E.
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationAn Observational Descriptive Cross-Sectional Study of 200 Iraqi Adult Patients with Ankylosing Spondylitis: Analysis of Ocular Manifestations
An Observational Descriptive Cross-Sectional Study of 200 Iraqi Adult Patients with Ankylosing Spondylitis: Analysis of Ocular Manifestations Khudair Al-Bedri 1 Najah K. Mohammad Al-Quriashi 2 Faiq I.
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More informationAmerican Journal of Therapeutics
American Journal of Therapeutics Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: A case report with a review of literature.
More informationEfficacy of anti tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta analysis
Wu et al. BMC Musculoskeletal Disorders (2015) 16:19 DOI 10.1186/s12891-015-0489-2 RESEARCH ARTICLE Open Access Efficacy of anti tumor necrosis factor therapy for extra-articular manifestations in patients
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationUveitis of spondyloarthritis in Indian subcontinent: a cross sectional study
International Journal of Advances in Medicine Ninan F et al. Int J Adv Med. 2017 Oct;4(5):1441-1446 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20174300
More informationM Rudwaleit, 1 E Rødevand, 2 P Holck, 3 J Vanhoof, 4 M Kron, 5 S Kary, 5 H Kupper 5. Extended report
1 Charité University Medicine Berlin, Benjamin Franklin Campus, Berlin, Germany; 2 St Olavs Hospital, Trondheim, Norway; 3 Regionshospitalet Silkeborg, Silkeborg, Denmark; 4 University Hasselt, Hasselt,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationRadiographic sacroiliitis develops predictably over time in a cohort of familial spondyloarthritis followed longitudinally
RHEUMATOLOGY Rheumatology 2017;56:811 817 doi:10.1093/rheumatology/kew496 Advance Access publication 4 February 2017 Original article Radiographic sacroiliitis develops predictably over time in a cohort
More informationIsoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
ORIGINAL ARTICLE 2017 Mar 13. [Epub ahead of print] Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationPsychological status is associated with drug efficacy in patients with ankylosing spondylitis
International Journal of Clinical Rheumatology Psychological status is associated with drug efficacy in patients with ankylosing Background: Quality of life in patients with Ankylosing Spondylitis (AS)
More informationT he spondyloarthritides (SpA) comprise five subtypes:
1305 EXTENDED REPORT Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept M Rudwaleit*, X
More informationSpA non-radiografica: fase precoce di spondilite anchilosante o altro?
Rheumatology Department of Lucania, S. Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Ignazio Olivieri Disclosures
More informationSustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis E. Martín-Mola 1, J. Sieper 2, M. Leirisalo-Repo 3, B.A.C.
More informationAnti-TNF-α Therapy for Ankylosing Spondylitis
Original Article Clinics in Orthopedic Surgery 2010;2:28-33 doi:10.4055/cios.2010.2.1.28 Anti-TNF-α Therapy for Ankylosing Spondylitis Jung-Hwan Son, MD, Sang-Won Cha, MD Department of Orthopedic Surgery,
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationCombined Infliximab and Rituximab in Necrotising Scleritis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More information2004 Health Press Ltd.
... Ankylosing spondylitis Maxime Dougados MD Professor of Rheumatology Hôpital Cochin René Descartes University Paris, France Désirée van der Heijde MD PhD Professor of Rheumatology University Hospital
More informationThe prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis
The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis G. Bornstein 1,2, M. Lidar 3, P. Langevitz 3, A. Fardman 2, I. Ben-Zvi 4, C. Grossman 4 1
More informationWho gets EIMs? Dr Tim Orchard St Mary s Hospital & Imperial College London
Who gets EIMs? Dr Tim Orchard St Mary s Hospital & Imperial College London Background Extraintestinal manifestations of IBD are well recognised. They include:- Arthritis - peripheral and axial Eye complications
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationThe Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2016.79.4.274 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2016;79:274-281 The Younger Patients Have More Better Prognosis in Limited Disease
More informationadalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)
adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationIs the Serum Uric Acid Level Independently Associated with Incidental Urolithiasis?
pissn: 2093-940X, eissn: 2233-4718 Journal of Rheumatic Diseases Vol. 25, No. 2, April, 2018 https://doi.org/10.4078/jrd.2018.25.2.116 Original Article Is the Serum Uric Acid Level Independently Associated
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationSpondyloarthritis: Practice. New Concepts in. Epidemiology and Clinical
New Concepts in Spondyloarthritis: Epidemiology and Clinical Practice Atul Deodhar MD Professor of Medicine Oregon Health & Science University Portland, OR Northwest Rheumatism Society, Seattle, April
More informationAnkylosing spondylitis functional and activity indices in clinical practice
Journal of Medicine and Life Vol. 7, Issue 1, JanuaryMarch 2014, pp.7883 Ankylosing spondylitis functional and activity indices in clinical practice Popescu C* **, Trandafir M*, Bădică AM*, Morar F*, Predeţeanu
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationWhat is Axial Spondyloarthritis?
Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy
More informationFate of Abstracts Presented at the Korean College of Rheumatology Annual Scientific Meetings
pissn: 2093-940X, eissn: 2233-4718 Journal of Rheumatic Diseases Vol. 26, No. 1, January, 2019 https://doi.org/10.4078/jrd.2019.26.1.41 Original Article Fate of Abstracts Presented at the Korean College
More informationA Tailored Approach to Uveitis and Associated Systemic Conditions Anthony DeWilde O.D.
A Tailored Approach to Uveitis and Associated Systemic Conditions Anthony DeWilde O.D. I. Introduction II. III. IV. A. Why I am giving this talk B. What to take from lecture Diagnosis 1. Better understanding
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More information37 year old male with several year history of back pain
37 year old male with several year history of back pain Inflammatory Low Back Pain Clues onset before the age of 40 years insidious onset, chronic (>3 months) pain morning stiffness for longer than 30
More informationA mong the inflammatory rheumatic diseases
659 REVIEW Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care J Sieper, M Rudwaleit... An earlier diagnosis of ankylosing spondylitis
More informationDo HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation
Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging? Results from the DESIR cohort of patients with recent onset axial spondyloarthritis Ho Yin Chung
More informationHumira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018
Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 POLICY A. INDICATIONS The indications below including
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More information2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material
2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis Online supplementary material 1. Introduction A systematic literature review (SLR) was performed to inform the
More informationAcute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye
Curr Rheumatol Rep (2015) 17:59 DOI 10.1007/s11926-015-0536-x SPONDYLOARTHRITIS (MA KHAN, SECTION EDITOR) Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye Muhammad A. Khan 1 & Muhammad
More informationDr Tracey Kain. Associate Professor Ed Gane
Associate Professor Ed Gane New Zealand Liver Transplant Unit Auckland Dr Tracey Kain Consultant Rheumatologist Grace Orthopaedic Centre Tauranga Hospital Tauranga 7:00-7:55 Abbvie Breakfast Session 1.
More informationScottish Medicines Consortium
Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional
More informationProgression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis
ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 6, June 2016, pp 1415 1421 DOI 10.1002/art.39542 VC 2016, American College of Rheumatology Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationMRI of the Sacroiliac Joints in Patients with Moderate to Severe Ankylosing Spondylitis
MRI of Sacroiliac Joints in Patients with nkylosing Spondylitis Musculoskeletal Imaging Original Research M E D E N T U R I L I M G I N G JR 2006; 187:1420 1426 0361 803X/06/1876 1420 merican Roentgen
More informationA Case of Infliximab-induced Multifocal Motor Neuropathy in a Patient with Rheumatoid Arthritis and Literature Review
Journal of Rheumatic Diseases Vol. 23, No. 4, August, 206 http://dx.doi.org/0.4078/jrd.206.23.4.250 Case Report A Case of Infliximab-induced Multifocal Motor Neuropathy in a Patient with Rheumatoid Arthritis
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationChapter 2. Overview of ankylosing spondylitis
Chapter 2 Overview of ankylosing spondylitis The concept and classification of spondyloarthritis The term spondyloarthritis (SpA) comprises AS, reactive arthritis, arthritis/spondylitis associated with
More informationJournal of Rheumatic Diseases Vol. 23, No. 4, August, 2016
Journal of Rheumatic Diseases Vol. 23, No. 4, August, 2016 http://dx.doi.org/10.4078/jrd.2016.23.4.234 Original Article Human Leukocyte Antigen B27 and Juvenile Idiopathic Arthritis and Classification
More informationMonitoring of the patients treated by Anti-TNFα : a step towards the personalized medicine.
10 th World Congress on Inflammation Paris (France) Satellite Symposium June 27 th 2011 Monitoring of the patients treated by Anti-TNFα : a step towards the personalized medicine. 1 Introduction Pr. Xavier
More informationConcept of Spondyloarthritis (SpA)
Concept of Spondyloarthritis (SpA) Spondyloarthritis: Characteristic Parameters Used for Diagnosis I Symptoms Inflammatory back pain Imaging Lab ESR/CRP Patient s history Good response to NSAIDs Spondyloarthritis-Characteristic
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationIndirect comparison of anti-tnf-α agents for active ankylosing spondylitis: mixed treatment comparison of randomised controlled trials
Indirect comparison of anti-tnf-α agents for active ankylosing spondylitis: mixed treatment comparison of randomised controlled trials T. Shu 1, G.H. Chen 2, L. Rong 1, F. Feng 1, B. Yang 1, R. Chen 1,
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationSarcoidosis: is there a role for anti-tnf-α?
Sarcoidosis: is there a role for anti-tnf-α? Abstract In severe cases of sarcoidosis treatment can be very difficult. The common treatment strategies might be failing. Tumour necrosis factor (TNF) α therapy
More informationThe effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic
More informationDo extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS
Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS I. Essers 1, S. Ramiro 2, C. Stolwijk 1, M. Blaauw 1, R. Landewé 3, D. van der Heijde 2, F. Van
More informationMedication Prior Authorization Form
Policy Number: 1055 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationImpact of Chronic Conditions on Health-Related Quality of Life
BURDEN OF ILLNESS Overview Impact of Chronic Conditions on Health-Related Quality of Life Chronic joint pain conditions have an important impact on health-related quality of life Note: a larger negative
More informationPrevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients
Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients J. Payet, L. Gossec, S. Paternotte, V. Burki, A. Durnez, M. Elhai, I. Fabreguet, E. Koumakis,
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationAnkylosing Spondylitis. DR. Milt Baker SEA Courses 2017
Ankylosing Spondylitis DR. Milt Baker SEA Courses 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationAnja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2
Weiß et al. Arthritis Research & Therapy 2014, 16:R35 RESEARCH ARTICLE Open Access Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationMagnetic Resonance Imaging of Inflammatory Lesions in the Spine in Ankylosing Spondylitis Clinical Trials: Is Paramagnetic Contrast Medium Necessary?
Magnetic Resonance Imaging of Inflammatory Lesions in the Spine in Ankylosing Spondylitis Clinical Trials: Is Paramagnetic Contrast Medium Necessary? KAY-GEERT A. HERMANN, ROBERT B.M. LANDEWÉ, JÜRGEN BRAUN,
More informationTreatment of ankylosing spondylitis: focus on etanercept
REVIEW Treatment of ankylosing spondylitis: focus on etanercept Tracy Frech University of Utah, Division of Rheumatology, UT, USA Abstract: Ankylosing spondylitis is a chronic inflammatory condition which
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue
More informationEligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS
Eligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS Abstract Background The Ankylosing Spondylitis Disease Activity Score (ASDAS) has been developed as a composite disease activity measure
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationReview Article Gender and Spondyloarthropathy-Associated Uveitis
Ophthalmology Volume 2013, Article ID 928264, 6 pages http://dx.doi.org/10.1155/2013/928264 Review Article Gender and Spondyloarthropathy-Associated Uveitis Wendy M. Smith MayoClinic,200FirstStreetSW,Rochester,MN55905,USA
More informationMycobacterial diseases developed during anti-tumour necrosis factor-a therapy
ORIGINAL ARTICLE PULMONARY INFECTIONS Mycobacterial diseases developed during anti-tumour necrosis factor-a therapy Jung-Wan Yoo 1, Kyung-Wook Jo 1, Bo-Hyung Kang 1, Mi Young Kim 2, Bin Yoo 3, Chang-Keun
More informationThis is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis.
This is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/98736/ Version: Accepted Version
More informationEtanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
Adv Ther (2012) 29(8):691 697. DOI 10.1007/s12325-012-0039-3 ORIGINAL RESEARCH Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan Benjamin
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationComplication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers A. Ruyssen-Witrand, L. Gossec, C. Salliot, M. Luc, M. Duclos, S. Guignard, M.
More informationLiterature Review. Biological therapy in treatment of uveitis. Contemporary trends. A.V. Zborovskaia, Dr Sc (Med), A.E. Dorokhova, Cand Sc (Med)
Literature Review Biological therapy in treatment of uveitis. Contemporary trends A.V. Zborovskaia, Dr Sc (Med), A.E. Dorokhova, Cand Sc (Med) Filatov Institute of Eye Diseases and Tissue Therapy of NAMS
More informationInfliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)
Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective
More informationORIGINAL ARTICLE. Abstract INTRODUCTION
International Journal of Rheumatic Diseases 2016 ORIGINAL ARTICLE Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective
More informationKey words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, treatment access
6, 21...,.,..,..,. - (RA) -,. (AS) (PsA). (Disease-modifying antirheumatic drugs, DMARDs). DMARDs 21. - RA, AS PsA. 21. RA, DMARDs. Leflunomide (Arava)., RA Methotrexate Leflunomid. DMARDs - 5 29. - RA
More informationThe spondyloarthritides encompass various clinical
O r i g i n a l A r t i c l e Clinical Update on Spondyloarthritis Isabelle Hébert MD FRCPC, Isabelle Fortin MD About the Authors Isabelle Hébert (far left) is a general internist in Chandler, Gaspé Peninsula,
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 20 September 2007 Product name: Remicade Procedure number: EMEA/H/C/240/II/95 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20)
More informationPREVALENCE OF SPONDYLOARTHROPATHY IN PUERTO RICAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PREVALENCE OF SPONDYLOARTHROPATHY IN PUERTO RICAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE Introduction: Inflammatory arthritis is the most common extraintestinal manifestation in patients with inflammatory
More information